Skip to main content

Table 1 Modulatory effect of luteolin on autophagy in cancer cell lines

From: Autophagy regulation using luteolin: new insight into its anti-tumor activity

Drug Cancer cell line IC50 Effect on autophagy Dose Period of experiment (h) Results Ref
Luteolin PC-12 Inhibition 100 µM 24 Reducing tumor proliferation [34]
Luteolin Liver cancer cells Inhibition 20 µM 24 Sensitized human liver cancer cells to TRAIL-induced apoptosis [35]
Luteolin Human Multiple Myeloma Cell RPMI-8226 Induction 20–80 µmol/L 24 and 48  Providing a decrease in the proliferation of tumor cells [36]
Luteolin and cisplatin Ovarian cancer cell Inhibition 20 and 40 µM 24 Promoted the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy [37]
Luteolin SMMC-7721 cells Induction 0, 12.5, 25, 50, 100 and 200 µM 24, 48 and 72 Improving apoptotic cell death [38]
Luteolin and doxorubicin Human osteosarcoma U2OS cells Induction 10, 50, 100 and 200 µM 24 Improving doxorubicin-mediated autophagy and decreasing osteosarcoma viability [39]
Luteolin and Chloroquine Cutaneous squamous cell carcinoma (MET4 cell) Induction 50 mmol/L 24 Chloroquine enhanced the cell death inducing effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells [40]
Luteolin NCI-H460 lung carcinoma cells. Induction 200 mmol/L 24 Induction of endoplasmic reticulum stress-mediated apoptosis and non-canonical autophagy [41]
Luteolin Colon cancer cells (HCT116) 27.61 ± 1.28 Induction 25 and 50 µM 24 Impaired hypoxia adaptation and progression in human colon cancer cells [42]
Luteolin Human colon cancer (SW620) cells 48.8 ± 1.6 µM Induction 1, 2, 5, and 10 µM 24 Induction of forkhead box O3a (FOXO3a) activation-medited autophAGY [43]
\